Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

NCT04513639 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT04513639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04513639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
Lead sponsor
Oslo University Hospital
Phase
Phase 2/3
Overall status
Recruiting
Start date
August 27, 2020
Completion date
June 1, 2032
Enrollment
176 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma